9/25/2009
Piper Jaffray & Co.
TranS1's solid clinical outcomes continue to drive interest and adoption of its AxiaLIF procedure, despite the reimbursement challenges that emerged in 2Q08. In addition, this week's SRS meeting highlighted the company's successful entrance into the clinically demanding market for adult idiopathic scoliosis (AIS) and complex spine, which we believe could help to offset the slowdown in its degenerative spine business. Visibility into near-term results remains difficult, however we view the stock as very attractive and expect TSON to significantly outperform our universe over the next twelve months.
View the attachment

